CorMedix Inc. (CRMD)
10.83
-0.35 (-3.09%)
At close: Feb 20, 2025, 3:59 PM
10.82
-0.09%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 10.76 |
| Market Cap | 657.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -13.54 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11.09 |
| Volume | 713,966 |
| Avg. Volume (20D) | 1,041,211 |
| Open | 11.18 |
| Previous Close | 11.18 |
| Day's Range | 10.63 - 11.09 |
| 52-Week Range | 3.03 - 13.85 |
| Beta | undefined |
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical setting...
Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2010
Employees 82
Stock Exchange NASDAQ
Ticker Symbol CRMD
Website https://www.cormedix.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CRMD stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 47.74% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
CorMedix Inc. is scheduled to release its earnings on Mar 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+29.89%
CorMedix shares are trading higher after the compa...
Unlock content with
Pro Subscription
2 months ago
+9.24%
CoreMedix shares are trading higher after the company announced it will be added to the Nasdaq Biotechnology Index.
